Schedule 13D ownership disclosure

HELIX ACQUISITION CORP II

Class A ordinary shares, $0.0001 par value per share · CUSIP: G4444H101

Event date: 2025-02-28

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Helix Holdings II LLCReported CIK 0001869101

    Shares: 4,989,000.00 · Class: 21.33%

  • Cormorant Private Healthcare Fund III, LPReported CIK 0001817320

    Shares: 1,427,040.00 · Class: 7.55%

  • Cormorant Private Healthcare GP III, LLC

    Shares: 1,427,040.00 · Class: 7.55%

  • Bihua ChenReported CIK 0001599214

    Shares: 7,389,000.00 · Class: 31.59%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-020316
Form type
SCHEDULE 13D/A
Filer
BridgeBio Oncology Therapeutics, Inc.
CIK
CIK 1869105
Filed
Mar 04, 2025
Reporting period
Feb 28, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub